Accessibility Menu
Herborium Group logo

Herborium Group(OTC) HBRM

Current Price$0.00
Market Cap$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-89%
1 Year+0%
1 Month+9,900%
Herborium Group last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-24
Herborium Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-17
1 month+9,900%USD 0.002026-06-24
3 month+0%USD 0.002026-04-24
Year to date+100%USD 0.002025-12-31
1 year+0%USD 0.002025-07-24
3 year+0%USD 0.002023-07-25
5 year-88.89%USD 0.002021-07-23
Since inception-100%USD 60.002006-09-19

Herborium Group Financials at a Glance

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$786.95K

Net Income (TTM)

-$230.74K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-10.24 (Low)

Price

$0.00

Volume

116,061

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jan 29, 2025

HBRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Herborium Group

Herborium Group, Inc. specializes in botanical therapeutics, focusing on the development and commercialization of plant-based medicinal products. The company offers a range of solutions targeting dermatological issues, sexual health, and energy enhancement.

Products and Services
  • AcnEase, an herbal treatment for hormonal acne and Rosacea
  • Non-prescription sexual health products for various dysfunctions
  • Lasting Energy, an herbal supplement for energy depletion and hangover relief
Growth Outlook
  • Recent quarterly revenue increased to $29,250, showing potential for growth
  • Strong gross profit margin of 52.1% in the latest quarter indicates product viability
  • Expansion into the UK and mainland Europe enhances market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of $1,000,000 reflects ongoing operational activity
  • Net income for the latest quarter was -$26,750, indicating ongoing investment in growth
  • Cash flow from operations improved significantly, reaching $101,420 in Q4 2023
Herborium Group, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic products. The company has developed a unique portfolio of herbal solutions that cater to various health needs, including skin conditions and sexual health. The recent increase in quarterly revenue and strong gross profit margins suggest that the company is on a path to potential profitability. The growth outlook appears promising, with the company actively expanding its market presence in the UK and Europe. The financial highlights indicate a commitment to operational growth, despite recent net income losses. The improvement in cash flow from operations is a positive sign, reflecting the company's ability to generate cash even in challenging financial conditions. Overall, Herborium Group, Inc. presents an intriguing opportunity for investors interested in the healthcare and botanical therapeutics sectors. The company's focus on innovative, plant-based solutions aligns with growing consumer demand for natural health products.
AI Generated • Jul 25, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

6

CEO

Agnes Paulina Olszewski, PhD, MBA

Website

www.herborium.com

Headquarters

Sugar Land, TX 77478, US

HBRM Financials

Key Financial Metrics (TTM)

Gross Margin

61.02%

Operating Margin

-36.90%

Net Income Margin

-29.32%

Return on Equity

6.01%

Return on Capital

N/A

Return on Assets

-307.24%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.42B

Volume

116.06K

Avg. Volume

518.87K

Financials (TTM)

Gross Profit

$480.20K

Operating Income

-$290.35K

EBITDA

-$290.35K

Operating Cash Flow

$197.07K

Capital Expenditure

$0.00

Free Cash Flow

$197.07K

Cash & ST Invst.

$3.50K

Total Debt

$1.07M

Herborium Group Performance Analysis

Herborium Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-11-30USD 1,133,1007.8%
20232023-11-30USD 1,119,420-1.2%
20242024-11-30USD 1,051,000-6.1%
20252025-11-30USD 788,250-25.0%
Herborium Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-31-14.3%
Q42025-11-30615.4%
Q12026-02-28-37.2%
Q22026-05-31-89.1%
Herborium Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-11-30USD 0.00N/A
20232023-11-30USD 0.00N/A
20242024-11-30USD 0.00N/A
20252025-11-30USD 0.00N/A
Herborium Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-31N/A
Q42025-11-30N/A
Q12026-02-28N/A
Q22026-05-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$29.25K

-58.2%

Gross Profit

$15.25K

-62.7%

Gross Margin

52.14%

N/A

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$570.95K

N/A

Employees

2

N/A

Net Income

-$26.75K

-41.5%

EBITDA

-$26.75K

-41.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.50K

-50.0%

Total Debt

$1.07M

-8.6%

Accounts Receivable

$4.85K

-50.3%

Inventory

$2.50K

-75.0%

Long Term Debt

$667.50K

+0.0%

Short Term Debt

$401.59K

-19.9%

Return on Assets

-3.07%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

-$5.60K

-103.4%

Operating Cash Flow

-$5.60K

-103.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MJNAMedical Marijuana, Inc.
$0.00+0.00%
CTTHCTT Pharmaceutical Holdings, Inc.
$0.07+8.02%
PCYNProcyon Corporation
$0.26+0.00%
EDXCEndexx Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About HBRM

What is the current price of Herborium Group?

Herborium Group is trading at $0.00 per share.

What is the 52-week range for Herborium Group?

Over the past 52 weeks, Herborium Group has traded between $0.00 and $0.00.

How much debt does Herborium Group have?

As of the most recent reporting period, Herborium Group reported total debt of $1.07M.

How much cash does Herborium Group have on hand?

Herborium Group reported $3.50K in cash and cash equivalents in its most recent financial results.

What is Herborium Group’s dividend yield?

Herborium Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services